Merus (MRUS) and Biohaven (BHVN) said Sunday they are partnering to co-develop three bispecific therapies using Merus' Biclonics platform and Biohaven's technologies.
Financial terms of the research collaboration and license agreement were not disclosed.
The collaboration has "the potential to significantly benefit patients across various cancer types through an enhanced efficacy and safety profile," said Brian Lestini, president of oncology at Biohaven.
Merus will receive a payment and license fee for the first ADC program, while preclinical costs will be split, with Merus covering bispecific antibody generation and Biohaven handling ADC generation cost, the companies added.
Both companies plan to share further development and marketing costs if the programs advance, they said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.